A recent phase 2 trial investigated the triple biased GLP-1/GIP/GCC receptors agonist retatrutide (LY3437943) in 338 patients with a mean age of 48 years and BMI of 37.3 kg/m 2 without diabetes (prediabetes in 36% participants) showing BW and WC reduction ranging from 8.7% to 24.2% and 6.5 cm to 19.6 cm in the 1 mg and 12 mg dose groups, respectively, at 48 weeks 41
Both promise regenerative benefits
Complete brief intake form, review medical history, and discuss any concerns or questions with our healthcare professional
In murine models, PCS treatment reduced pro-inflammatory factors (IL-1, IL-6, CCL3, and TNF-) and significantly increased the anti-inflammatory factor IL-10, thereby further alleviating hepatic inflammation
Administering at a similar time each night helps in aligning with the bodys circadian rhythm and supports sleep-wake cycle stability
Is not a question about sudden change